Symposium Knochenveränderungen bei malignen Tumoren

  • R. Ziegler
  • G. R. Mundy
  • B. Krempien
  • H. von Lilienfeld-Toal
  • J. Freyschmidt
  • W. Schreml
  • H. W. Minne
Conference paper
Part of the Verhandlungen der Deutschen Gesellschaft für innere Medizin book series (VDGINNERE, volume 89)

Zusammenfassung

Verlängerte Lebenszeiten und verbesserte Behandlungsmöglichkeiten für Tumorerkrankungen bringen es mit sich, daß paraneoplastische Phänomene wie Kalziumstoffwechselstörungen und Osteopathien häufiger zum Problem werden. Die aufmerksamer gewordenen Ärzte tragen dementsprechend Vorsorge, daß der Patient nicht durch derartige Komplikationen zusätzlich gefährdet wird.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Burkhardt E, Kistler HJ (1981) Hypercalciämie bei hospitalisierten Patienten. Schweiz Med Wochenschr 111: 2017–2023PubMedGoogle Scholar
  2. Hickey RC, Samaan NA, Jackson GL (1981) Hypercalcemia in patients with breast cancer. Arch Surg 116: 545–552PubMedCrossRefGoogle Scholar
  3. Lafferty FW (1966) Pseudohyperparathyreoidism. Medicine (Baltimore) 45: 247–253CrossRefGoogle Scholar
  4. McDonnell GD, Dunstan CR, Evans RA, Carter JN, Hills E, Wong SYP, Mcneil DR (1982) Quantitative bone histology in the hypercalcemia of malignant disease. J Clin Endocrinol Metab 55: 1066–1072PubMedCrossRefGoogle Scholar
  5. Villalon AH, Tattersall HHN, Fox RM, Woods RL (1979) Hypercalcemia after tamoxifen for breast cancer: a sign of tumour response? Br Med J 2: 1329–1330PubMedCrossRefGoogle Scholar

References

  1. Binstock ML, Mundy GR (1980) Effects of calcitonin and glucocorticoids in combination in hypercalcemia of malignancy. Ann Intern Med 93: 269–272PubMedGoogle Scholar
  2. Dominguez JH, Mundy GR (1980) Monocytes mediate osteoclastic bone resorption by prostaglandin production. Calcif Tissue Int 31: 29–34PubMedCrossRefGoogle Scholar
  3. Eilon G, Mundy GR (1978) Direct resorption of bone by human breast cancer cells in vitro. Nature 276: 726–728PubMedCrossRefGoogle Scholar
  4. Mundy GR, Luben RA, Raisz LG, Oppenheim JJ, Buell DN (1974) Bone-resorbing activity in supernatants from lymphoid cell lines. N Engl J Med 290: 867–871PubMedCrossRefGoogle Scholar
  5. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE (1974) Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 291: 1041–1046PubMedCrossRefGoogle Scholar
  6. Mundy GR, Shapiro JL, Bandelin JG, Canalis EM, Raisz LC (1976) Direct stimulation of bone resorption by thyroid hormones. J Clin Invest 58: 529–534PubMedCrossRefGoogle Scholar
  7. Mundy GR, Altman AJ, Gondek M, Bandelin JG (1977) Direct resorption of bone by human monocytes. Science 196: 1109–1111PubMedCrossRefGoogle Scholar
  8. Mundy GR, Rick ME, Turcotte R, Kowalski MA (1978) Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia – Role of an osteoclast activating factor-like substance and mechanism of action for glucocorticoid therapy. Am J Med 65: 600–606PubMedCrossRefGoogle Scholar
  9. Mundy GR, Varani J, Orr W, Gondek MD, Ward PA (1978) Resorbing bone is chemotactic for monocytes. Nature 275: 132–135PubMedCrossRefGoogle Scholar
  10. Mundy GR, Cove DH, Fisken R (1980) Primary hyperparathyroidism: Changes in the pattern of clinical presentation. Lancet 1: 1317–1320PubMedCrossRefGoogle Scholar
  11. Mundy GR, Raisz LG (1981) Disorders of bone resorption. In: Bronner F, Coburn JW (eds) Disorders of mineral metabolism, vol III. Academic Press, New York, pp 1–66Google Scholar
  12. Mundy GR, Martin TJ (1982) Hypercalcemia of malignancy — Pathogenesis and treatment. Metabolism 31: 1247–1277PubMedCrossRefGoogle Scholar
  13. Mundy GR, Wilkinson R, Heath DA (1983) Comparative study of available medical therapy for hypercalcemia of malignancy. Am J Med 74: 421–432PubMedCrossRefGoogle Scholar
  14. Orr W, Varani J, Gondek MD, Ward PA, Mundy GR (1979) Chemotactic response of tumor cells to products of resorbing bone. Science 203: 176–179PubMedCrossRefGoogle Scholar
  15. Raisz LG, Luben RA, Mundy GR, Dietrich JW, Horton JE, Trummel CL (1975) Effect of osteoclast activating factor from human leukocytes on bone metabolism. J Clin Invest 56: 408–413PubMedCrossRefGoogle Scholar
  16. Strumpf M, Kowalski MA, Mundy GR (1978) Effects of glucocorticoids on osteoclast-activating factor. J Lab Clin Med 92: 772–778PubMedGoogle Scholar
  17. Yoneda T, Mundy GR (1979) Monocytes regulate osteoclast-activating factor production by releasing prostaglandins. J Exp Med 150: 338–350PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Bockman RS (1980) Hypercalcemia in malignancy. Clin Endocrinol Metab 9: 317–333PubMedCrossRefGoogle Scholar
  2. 2.
    Raskin P, McClain CJ, Medsger TA (1973) Hypocalcemia associated with metastatic bone disease. Arch Intern Med 132: 539–543PubMedCrossRefGoogle Scholar
  3. 3.
    Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE (1980) Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med 303: 1377–1383PubMedCrossRefGoogle Scholar
  4. 4.
    Salassa RM, Jowsey J, Arnaud CD (1970) Hypophosphatemic osteomalacia associated with “nonendocrine” tumors. N Engl J Med 283: 65–70PubMedCrossRefGoogle Scholar
  5. 5.
    Williams SJ, Green M, Kerr IH (1977) Detection of bone metastases in carcinoma of bronchus. Br Med J 1: 1004PubMedCrossRefGoogle Scholar
  6. 6.
    Galasko CSP (1977) Skeletal metastases and mammary cancer. Ann R Coll Surg Engl 50: 3–28Google Scholar
  7. 7.
    Drezner MK, Lebovitz HE (1978) Primary hyperparathyroidism in paraneoplastic hypercalcemia. Lancet 2: 1004–1006CrossRefGoogle Scholar
  8. 8.
    Hickey RC, Samaan NA, Jackson GL (1981) Hypercalcemia in patients with breast cancer. Osseous metastases, hyperplastic parathyroid tissue, or pseudo hyperparathyroidism? Arch Surg 116: 545–552PubMedCrossRefGoogle Scholar
  9. 9.
    Benson RC, Riggs BL, Pickard BM, Arnaud CD (1974) Radioimmunoassay of parathyroid hormone in hypercalcemic patients with malignant disease. Am J Med 56: 821–826PubMedCrossRefGoogle Scholar
  10. 10.
    Lilienfeld-Toal H v, Niederle N, Keck E (1981) Elevated immunoreactive parathyroid hormone (iPTH) in normocalcemic lung cancer. Clin Res 29: 424AGoogle Scholar
  11. 11.
    Lilienfeld-Toal H v, Niederle N (1983) Increased immunoreactive parathyroid hormone in lung cancer (submitted)Google Scholar
  12. 12.
    Franck H, Hartlapp JH, Lilienfeld-Toal H v (1982) Increased set-point of parathyroid secretion induced by chronic hypercalcemia of non parathyroid reason. Eur J Clin Invest (Suppl) 12: 69CrossRefGoogle Scholar
  13. 13.
    Seyberth HW, Segre GV, Morgan JL, Sweetman BJ, Potts JT, Oates JA (1975) Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med 293: 1278–1283PubMedCrossRefGoogle Scholar
  14. 14.
    Brenner DE, Harvey HA, Lipton A, Demers L (1982) A study of prostaglandin E2, parathormone and response to indomethacin in patients with hypercalcemia of malignancy. Cancer 49: 556–561PubMedCrossRefGoogle Scholar
  15. 15.
    Durie BGM, Salmon SE, Mundy GR (1981) Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma. Br J Haematol 47: 21–30PubMedCrossRefGoogle Scholar
  16. 16.
    Luben RA (1981) Evidence for the participation of osteoclast activating factor in disease processes in vivo. In: Cohn DV et al. (eds) Hormonal control of calcium metabolism. Excerpta Medica 315–321Google Scholar
  17. 17.
    Kukreja SC, Shemerdiak WP, Lad TE, Johnson PA (1980) Elevated nephrogenous cyclic AMP with normal serum parathyroid hormone levels in patients with lung cancer. J Clin Endocrinol Metab 51: 167–169PubMedCrossRefGoogle Scholar

Literatur

  1. Braunstein EM (1980) Non-Hodgkin disease of bone: Radiographic correlation with the histological classification. Radiology 137: 643–646PubMedGoogle Scholar
  2. Dominok GW, Knoch HG (1977) Knochengeschwülste und geschwulstähnliche Knochenerkrankungen. Fischer, JenaGoogle Scholar
  3. Freyschmidt J (1980) Knochenerkrankungen im Erwachsenenalter. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  4. Spagnoli J, Gattoni F, Viganotti G (1982) Roentgenographic aspects of Non-Hodgkin-Lymphomas presenting with osseus lesions. Skeletal Radiol 8: 39–41PubMedCrossRefGoogle Scholar
  5. Uehlinger E (1981) Sekundäre Knochengeschwülste. In: Schinz HR et al. (Hrsg) Lehrbuch der Röntgendiagnostik. Thieme, Stuttgart New YorkGoogle Scholar

Literatur

  1. Chabner BA, Johnson RE, Young RC, Canllos GP, Hubbard SP, Johnson SK, DeVita VT Jr (1976) Sequential nonsurgical and surgical staging of non-Hodgkin lymphoma. Ann Intern Med 85: 149–154PubMedGoogle Scholar
  2. Chabner BA, Haskell CM, Canellos GP (1969) Destructive bone lesions in chronic granulocytic leukemia. Medicine (Baltimore) 48: 401–41Google Scholar
  3. Cortes EP, Holland JF, Wang IJ, Glidewell O (1975) Adriamycin (NSC-123127) in 87 patients with osteogenic sarcoma. Cancer Chemother Rep 6: 305–313Google Scholar
  4. Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Cancer 36: 842–854PubMedCrossRefGoogle Scholar
  5. Gilbert HA, Kagan AR (1976) Metastases: incidence, detection, and evaluation without histologic confirmation. In: Weiss L (ed) Fundamental aspects of metastasis. North Holland Publ. Comp., Amsterdam Oxford, pp 385–406Google Scholar
  6. Jaffe N (1972) Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 30: 1627–1631PubMedCrossRefGoogle Scholar
  7. Henderson ES (1977) Acute leukemia: general considerations. In: Williams WJ, Beutler E, Erslev AJ, Rundles RW (eds) Hematology, 2nd ed. McGraw-Hill, New York, pp 809–830Google Scholar
  8. Kyle RA (1975) Multiple myeloma. Review of 869 cases. Mayo Clin Proc 50: 29–40PubMedGoogle Scholar
  9. Lohrmann HP, Adam W, Heymer B, Kubanek B (1973) Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases. Ann Intern Med 79: 368–375PubMedGoogle Scholar
  10. Newcomer LN, Silverstein MB, Cadman EC, Farber LR, Bertino JR, Prosnitz LR (1982) Bone involvement in Hodgkin’s disease. Cancer 49: 338–342PubMedCrossRefGoogle Scholar
  11. Ochs IJ, Freeman AI, Douglass HO Jr, Higby DS, Mindell ER, Sinks LF (1978) Cis-dichlorodiammine-platinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 62: 239–245PubMedGoogle Scholar
  12. Pannuti F, Rossi AP, Marraro D, Strocchi E, Cricca A, Piana E, Pollutri E (1980) The natural history of cancer pain. In: Twycross RG, Ventafridda V (eds) The continuing care of terminal cancer patients. Pergamon Press, Oxford, pp 75–78Google Scholar
  13. Poppe H (1976) Röntgenologische Frühdiagnostik. Orthop Praxis 10: 933–938Google Scholar
  14. Pratt CB, Shanks EC, Hustu HO, Rivera G, Smith J, Mahesh Kumar AP (1977) Adjuvant multiple drug chemotherapy for osteogenic sarcoma of the extremity. Cancer 39: 51–57PubMedCrossRefGoogle Scholar
  15. Rosen G, Murphy ML, Huvos AG, Gutierrez A, Marcove R (1976) Chemotherapy, en bloc resection and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 37: 1–11PubMedCrossRefGoogle Scholar
  16. Rosen G, Huvos AG, Mosende C, Beattie EJ, Exelby PR, Caparros B, Marcove RC (1978) Chemotherapy and thoracotomy for metastatic osteogenic sarcoma. A model for adjuvant chemotherapy and the rationale for the timing of thoracic surgery. Cancer 41: 841–849PubMedCrossRefGoogle Scholar
  17. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG (1979) Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer 43: 2163–2177PubMedCrossRefGoogle Scholar
  18. Rosen G, Caparros B, Nirenberg A, Marcove RC, Huvos AG, Kosloff C, Lane J, Murphy ML (1981) Ewing’s sarcoma: Ten-Year experience with adjuvant chemotherapy. Cancer 47: 2204–2213PubMedCrossRefGoogle Scholar
  19. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, Marcove RC, Lane JM, Mehta B, Urban C (1982) Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: 1221–1230PubMedCrossRefGoogle Scholar
  20. Schreml W, Merkle W, Heimpel H (1981) Medikamentöse Schmerztherapie bei Krebspatienten. Med Klin 76: 43–47PubMedGoogle Scholar
  21. Schreml W (1983) Supportive Maßnahmen bei der internistischen Tumorbehandlung: Schmerztherapie. In: Drings P, Schreml W (Hrsg) Supportive Maßnahmen in der internistischen Tumorbehandlung. W. Zuckschwerdt Verlag, MünchenGoogle Scholar
  22. Silverberg E (1982) Cancer statistics 1982. CA 32: 15–31PubMedGoogle Scholar
  23. Sutow WW, Sullivan MP, Wilbur JR, Cangir A (1975) A study of adjuvant chemotherapy in osteogenic sarcoma. J Clin Pharmacol 7: 530–533Google Scholar
  24. Thomas LB, Forkner CE, Frei E, Byron EB, Stabenau JR (1961) The skeletal lesions of acute leukemia. Cancer 14: 608–621PubMedCrossRefGoogle Scholar

Copyright information

© J. F. Bergmann Verlag, München 1983

Authors and Affiliations

  • R. Ziegler
    • 1
  • G. R. Mundy
    • 2
  • B. Krempien
    • 3
  • H. von Lilienfeld-Toal
    • 4
  • J. Freyschmidt
    • 5
  • W. Schreml
    • 6
  • H. W. Minne
    • 7
  1. 1.Abt. Innere Medizin VI — Endokrinologie, Med. PoliklinikUniv. HeidelbergDeutschland
  2. 2.Dept. of Medicine/EndocrinologyThe Univ. of Texas Health Science CenterSan AntonioUSA
  3. 3.Patholog. Inst.Univ. HeidelbergDeutschland
  4. 4.Med. Univ.-Klinik VenusbergBonnDeutschland
  5. 5.Radiolog. KlinikKlinikum St.-Jürgen-StraßeBremenDeutschland
  6. 6.Abt. Innere Medizin IIIKlinikum der Univ. UlmDeutschland
  7. 7.Abt. für Innere Medizin VIMed. Univ.-Klinik HeidelbergDeutschland

Personalised recommendations